Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by TopBrokeron Mar 22, 2021 8:02pm
364 Views
Post# 32855596

OUT WITH THE REDUNDANT

OUT WITH THE REDUNDANTThe new people involved are not interested in a penny stock but are amazed that nobody has done a joint venture or partnership with Promis. The current board is inept and have damaged this Company for the past 6 years, with the exception of Dr.Neil Cashman. Elliott Goldstein and Gene Williams are light weights in the industry and talk a lot but did not deliver. Now at their age they finally see they cannot deliver and must step aside and let those with the clout to deliver on what Dr.Cashman has developed. Hopefully your CEO Goldstein will step aside earlier, but not before he cries for his money and shares, greedy Bas^^^^d. Now you will see things develop.

https://greylock.com/team/henry-mccance/
<< Previous
Bullboard Posts
Next >>